1. Home
  2. BRLT vs GRDX Comparison

BRLT vs GRDX Comparison

Compare BRLT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

N/A

Current Price

$1.52

Market Cap

25.5M

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.82

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRLT
GRDX
Founded
2005
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.5M
28.6M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
BRLT
GRDX
Price
$1.52
$4.82
Analyst Decision
Hold
Analyst Count
4
0
Target Price
★ $1.62
N/A
AVG Volume (30 Days)
58.8K
★ 109.3K
Earning Date
11-05-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
★ $437,483,000.00
N/A
Revenue This Year
$5.10
N/A
Revenue Next Year
$5.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.63
N/A
52 Week Low
$1.00
$1.87
52 Week High
$2.90
$6.93

Technical Indicators

Market Signals
Indicator
BRLT
GRDX
Relative Strength Index (RSI) 54.64 52.79
Support Level $1.26 $2.35
Resistance Level $1.63 $5.04
Average True Range (ATR) 0.08 0.54
MACD -0.00 -0.06
Stochastic Oscillator 63.64 38.17

Price Performance

Historical Comparison
BRLT
GRDX

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: